New drug combo for residual triple-negative breast cancer after surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer (no hormone receptors or HER2 protein).
- You had surgery and some cancer was still found in your breast or lymph nodes.
- You have not received a certain type of antibody-drug therapy or HER2-targeted drugs before.
- You do not have serious heart, lung, or immune system problems.
- You have not had another cancer in the last 5 years (except cured skin or cervical cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
This trial tests a new drug called Trastuzumab Rezetecan, either alone or combined with Bevacizumab, for people with a specific type of advanced triple-negative breast cancer that has been treated with up to two prior therapies. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new targeted drug called trastuzumab rezetecan (T-DXh) for patients with HER2-positive breast cancer who didn't have a complete response to standard chemotherapy and targeted drugs. The goal is to see if this new drug can help shrink remaining cancer.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.